SG11202011879RA - Ion channel modulators - Google Patents
Ion channel modulatorsInfo
- Publication number
- SG11202011879RA SG11202011879RA SG11202011879RA SG11202011879RA SG11202011879RA SG 11202011879R A SG11202011879R A SG 11202011879RA SG 11202011879R A SG11202011879R A SG 11202011879RA SG 11202011879R A SG11202011879R A SG 11202011879RA SG 11202011879R A SG11202011879R A SG 11202011879RA
- Authority
- SG
- Singapore
- Prior art keywords
- ion channel
- channel modulators
- modulators
- ion
- channel
- Prior art date
Links
- 102000004310 Ion Channels Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862677903P | 2018-05-30 | 2018-05-30 | |
US201862738508P | 2018-09-28 | 2018-09-28 | |
PCT/US2019/034653 WO2019232209A1 (en) | 2018-05-30 | 2019-05-30 | Ion channel modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202011879RA true SG11202011879RA (en) | 2020-12-30 |
Family
ID=68696775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202011879RA SG11202011879RA (en) | 2018-05-30 | 2019-05-30 | Ion channel modulators |
Country Status (13)
Country | Link |
---|---|
US (5) | US11866439B2 (zh) |
EP (1) | EP3801535A4 (zh) |
JP (3) | JP7359847B2 (zh) |
KR (1) | KR20210024500A (zh) |
CN (2) | CN112423760A (zh) |
AU (1) | AU2019278814A1 (zh) |
BR (1) | BR112020024379A2 (zh) |
CA (1) | CA3101324A1 (zh) |
IL (2) | IL309843A (zh) |
MX (2) | MX2020012838A (zh) |
SG (1) | SG11202011879RA (zh) |
TW (1) | TWI831786B (zh) |
WO (1) | WO2019232209A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
JP7105797B2 (ja) | 2016-11-28 | 2022-07-25 | プラクシス プレシジョン メディシンズ, インコーポレイテッド | 化合物及びその使用方法 |
WO2018148745A1 (en) | 2017-02-13 | 2018-08-16 | Praxis Precision Medicines , Inc. | Compounds and their methods of use |
WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
WO2019035951A1 (en) | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | COMPOUNDS AND THEIR METHODS OF USE |
AU2019278814A1 (en) * | 2018-05-30 | 2020-12-17 | Praxis Precision Medicines, Inc. | Ion channel modulators |
EA202190581A1 (ru) | 2018-08-20 | 2021-07-13 | Рогкон, Инк. | Антисмысловые олигонуклеотиды, нацеленные на scn2a, для лечения энцефалопатии scn1a |
US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
JP2023503343A (ja) * | 2019-11-26 | 2023-01-27 | プラクシス プレシジョン メディシンズ, インコーポレイテッド | イオンチャネルモジュレーター |
CN115038442A (zh) | 2019-11-27 | 2022-09-09 | 普拉西斯精密医药公司 | 离子通道调节剂的调配物及制备和使用离子通道调节剂的方法 |
WO2023211859A1 (en) * | 2022-04-26 | 2023-11-02 | Praxis Precision Medicines, Inc. | Treatment of neurological disorders |
WO2023211852A1 (en) * | 2022-04-26 | 2023-11-02 | Praxis Precision Medicines, Inc. | Treatment of neurological disorders |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
CA1080712A (en) | 1976-09-22 | 1980-07-01 | Jay D. Albright | Hypotensive agents |
US4230705A (en) * | 1976-09-22 | 1980-10-28 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety |
US4112095A (en) | 1976-10-07 | 1978-09-05 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents |
US4242515A (en) | 1979-03-28 | 1980-12-30 | American Cyanamid Company | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
GB9507348D0 (en) | 1995-04-08 | 1995-05-31 | Knoll Ag | Therapeutic agents |
US6589952B2 (en) * | 2000-07-14 | 2003-07-08 | Bristol-Myers Squibb Pharma Company | Imidazo[1,2-a]pyrazines for the treatment of neurological disorders |
WO2006061428A2 (en) | 2004-12-10 | 2006-06-15 | Universität Zürich | Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain |
WO2006133508A1 (en) | 2005-06-16 | 2006-12-21 | Bionomics Limited | Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene |
DK1966214T3 (en) * | 2005-12-21 | 2017-02-13 | Janssen Pharmaceutica Nv | TRIAZOLPYRIDAZINES AS TYROSINKINASA MODULATORS |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
KR100858357B1 (ko) | 2006-10-02 | 2008-09-11 | (주) 디지탈바이오텍 | 벤조퓨란계 유도체 화합물을 유효성분으로 함유하는인지기능 장애의 예방 및 치료용 조성물 |
FR2915198B1 (fr) | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
EA201070914A1 (ru) | 2008-02-06 | 2011-04-29 | Гайлид Сайэнсиз, Инк. | Применение ранолазина для лечения боли |
US20100113461A1 (en) | 2008-10-29 | 2010-05-06 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds |
WO2010074807A1 (en) | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators |
WO2010056865A1 (en) | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Quinoline derivatives as ion channel modulators |
RU2553451C2 (ru) | 2008-12-24 | 2015-06-20 | Биал-Портела Энд Ка, С.А. | Фармацевтические соединения |
NZ596078A (en) | 2009-05-12 | 2013-06-28 | Janssen Pharmaceuticals Inc | 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
RS56410B1 (sr) | 2009-07-27 | 2018-01-31 | Gilead Sciences Inc | Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala |
WO2011056985A2 (en) | 2009-11-04 | 2011-05-12 | Gilead Sciences, Inc. | Substituted heterocyclic compounds |
FR2953520B1 (fr) | 2009-12-04 | 2011-11-25 | Sanofi Aventis | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique |
US20130315895A1 (en) * | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
WO2012065297A1 (en) | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
US9139576B2 (en) | 2011-05-03 | 2015-09-22 | Merck Sharp & Dohme Corp. | Aminomethyl biaryl benzotriazole derivatives |
JP5934787B2 (ja) | 2011-05-10 | 2016-06-15 | ギリアード サイエンシーズ, インコーポレイテッド | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
NO3175985T3 (zh) | 2011-07-01 | 2018-04-28 | ||
EP2758053A1 (en) | 2011-09-21 | 2014-07-30 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
US9586963B2 (en) | 2011-09-27 | 2017-03-07 | Genfit | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists |
US20150344457A1 (en) | 2012-12-21 | 2015-12-03 | Epizyme, Inc. | Methods of inhibiting prmt5 |
KR20150131233A (ko) * | 2013-03-14 | 2015-11-24 | 제넨테크, 인크. | 치환된 트리아졸로피리딘 및 이의 사용 방법 |
US20140329755A1 (en) | 2013-05-01 | 2014-11-06 | Gilead Sciences, Inc. | Combination therapy for the treatment of arrhythmias or heart failure |
SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
ES2813450T3 (es) | 2013-08-19 | 2021-03-23 | Univ California | Compuestos y métodos para tratar un trastorno epiléptico |
GB201321740D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
KR101918375B1 (ko) | 2013-12-19 | 2018-11-13 | 길리애드 사이언시즈, 인코포레이티드 | 이온 채널 조정제로서의 융합된 헤테로시클릭 화합물 |
WO2015157955A1 (en) | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
WO2015194670A1 (ja) | 2014-06-20 | 2015-12-23 | 三菱化学株式会社 | ポリカーボネートジオールおよびその製造方法並びにそれを用いたポリウレタン |
TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | MnK抑制劑及其相關方法 |
WO2015197567A1 (en) | 2014-06-26 | 2015-12-30 | F. Hoffmann-La Roche Ag | Indolin-2-one or pyrrolo-pyridin-2-one derivatives |
JP2017001991A (ja) | 2015-06-11 | 2017-01-05 | 大日本住友製薬株式会社 | 新規ベンズオキサゾロン化合物 |
US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
WO2018098500A1 (en) | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
JP7105797B2 (ja) | 2016-11-28 | 2022-07-25 | プラクシス プレシジョン メディシンズ, インコーポレイテッド | 化合物及びその使用方法 |
WO2018148745A1 (en) | 2017-02-13 | 2018-08-16 | Praxis Precision Medicines , Inc. | Compounds and their methods of use |
WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
WO2019035951A1 (en) | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | COMPOUNDS AND THEIR METHODS OF USE |
AU2019278814A1 (en) * | 2018-05-30 | 2020-12-17 | Praxis Precision Medicines, Inc. | Ion channel modulators |
EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
JP2023503343A (ja) | 2019-11-26 | 2023-01-27 | プラクシス プレシジョン メディシンズ, インコーポレイテッド | イオンチャネルモジュレーター |
CN115038442A (zh) | 2019-11-27 | 2022-09-09 | 普拉西斯精密医药公司 | 离子通道调节剂的调配物及制备和使用离子通道调节剂的方法 |
-
2019
- 2019-05-30 AU AU2019278814A patent/AU2019278814A1/en active Pending
- 2019-05-30 MX MX2020012838A patent/MX2020012838A/es unknown
- 2019-05-30 CA CA3101324A patent/CA3101324A1/en active Pending
- 2019-05-30 TW TW108118813A patent/TWI831786B/zh active
- 2019-05-30 SG SG11202011879RA patent/SG11202011879RA/en unknown
- 2019-05-30 EP EP19810530.6A patent/EP3801535A4/en active Pending
- 2019-05-30 CN CN201980047216.4A patent/CN112423760A/zh active Pending
- 2019-05-30 BR BR112020024379-5A patent/BR112020024379A2/pt unknown
- 2019-05-30 WO PCT/US2019/034653 patent/WO2019232209A1/en active Application Filing
- 2019-05-30 CN CN202311479943.2A patent/CN117756800A/zh active Pending
- 2019-05-30 KR KR1020207037964A patent/KR20210024500A/ko not_active Application Discontinuation
- 2019-05-30 US US17/058,187 patent/US11866439B2/en active Active
- 2019-05-30 JP JP2021516850A patent/JP7359847B2/ja active Active
- 2019-05-30 IL IL309843A patent/IL309843A/en unknown
-
2020
- 2020-11-24 US US17/102,586 patent/US11014931B2/en active Active
- 2020-11-27 MX MX2024000150A patent/MX2024000150A/es unknown
- 2020-11-29 IL IL279064A patent/IL279064A/en unknown
-
2021
- 2021-03-26 US US17/214,343 patent/US11731976B2/en active Active
-
2022
- 2022-03-23 US US17/702,518 patent/US11731978B2/en active Active
-
2023
- 2023-08-21 US US18/236,156 patent/US20240132501A1/en active Pending
- 2023-08-21 JP JP2023133988A patent/JP2023144130A/ja active Pending
-
2024
- 2024-03-25 JP JP2024048085A patent/JP2024071530A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20240132501A1 (en) | 2024-04-25 |
TWI831786B (zh) | 2024-02-11 |
US11731978B2 (en) | 2023-08-22 |
US11014931B2 (en) | 2021-05-25 |
JP2021525800A (ja) | 2021-09-27 |
WO2019232209A1 (en) | 2019-12-05 |
CN117756800A (zh) | 2024-03-26 |
JP2024071530A (ja) | 2024-05-24 |
TW202012403A (zh) | 2020-04-01 |
MX2024000150A (es) | 2024-01-23 |
IL309843A (en) | 2024-02-01 |
JP7359847B2 (ja) | 2023-10-11 |
US20220024930A1 (en) | 2022-01-27 |
IL279064A (en) | 2021-01-31 |
EP3801535A4 (en) | 2022-03-02 |
US11731976B2 (en) | 2023-08-22 |
JP2023144130A (ja) | 2023-10-06 |
KR20210024500A (ko) | 2021-03-05 |
US11866439B2 (en) | 2024-01-09 |
MX2020012838A (es) | 2021-07-16 |
US20220220118A1 (en) | 2022-07-14 |
US20210163488A1 (en) | 2021-06-03 |
AU2019278814A1 (en) | 2020-12-17 |
BR112020024379A2 (pt) | 2021-03-02 |
CA3101324A1 (en) | 2019-12-05 |
CN112423760A (zh) | 2021-02-26 |
EP3801535A1 (en) | 2021-04-14 |
US20210087197A1 (en) | 2021-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279064A (en) | ion channel modulators | |
IL281946A (en) | ion channel modulators | |
PL3743406T3 (pl) | Modulatory tmem16a | |
EP4065124A4 (en) | ION CHANNEL MODULATORS | |
GB2596231B (en) | Modulators | |
SG11202008516XA (en) | Techniques for secure channel communications | |
GB202006708D0 (en) | ION source | |
IL267954B (en) | potassium channel modulators | |
GB2575342B (en) | Ion guide | |
GB2576242B (en) | Ion source | |
GB201711208D0 (en) | Ion channel inhibitors | |
GB202117519D0 (en) | Ion channel modulators | |
GB2585587B (en) | Modulators | |
GB201804229D0 (en) | ION Guide | |
GB2575770B (en) | Ion guide | |
GB2574796B (en) | Ion guide | |
GB201907760D0 (en) | Ion guide | |
GB201814739D0 (en) | Ion Guide | |
GB201808047D0 (en) | Ion guide | |
GB201802521D0 (en) | Field asymmetric ion mobility spectromentry system | |
EP3297990A4 (en) | MODULATORS OF SODIUM CHANNELS | |
AU2015901096A0 (en) | Sodium channel modulators |